Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Vir Biotechnology, Inc. (NASDAQ:VIR) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET

Company Participants

Jason O’Byrne – Executive VP & CFO
Marianne De Backer – CEO & Director
Mark D. Eisner – Executive VP & Chief Medical Officer
Mika Kakefuda Derynck – Executive Vice President of Therapeutic Head Oncology

Conference Call Participants

Avraham Leib Novick – Morgan Stanley, Research Division
Huidong Wang – Barclays Bank PLC, Research Division
Joseph Robert Stringer – Needham & Company, LLC, Research Division
Mazahir Lukman Alimohamed – Leerink Partners LLC, Research Division
Patrick Ralph Trucchio – H.C. Wainwright & Co, LLC, Research Division
Philip M. Nadeau – TD Cowen, Research Division
Sean McCutcheon – Raymond James & Associates, Inc., Research Division

Operator

Hello. Welcome to Vir Biotechnology’s Second Quarter 2025 Financial Results and Corporate Update Call. As a reminder, this conference call is being recorded. [Operator Instructions]

I will now turn the call over to Rich Lepke, Senior Director, Investor Relations. You may begin Mr. Lepke.

Unidentified Company Representative

Thank you, and good afternoon. With me today are Dr. Marianne De Backer, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; Jason O’Byrne, our Chief Financial Officer; and Dr. Mika Derynck, our Executive Vice President of Oncology, who will be available during the Q&A session.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company’s reports filed with the Securities and Exchange Commission including Forms 10-K, 10-Q and 8-K.